ATE260675T1 - Methoden zur behandlung der salzabhängigen hypertonie - Google Patents

Methoden zur behandlung der salzabhängigen hypertonie

Info

Publication number
ATE260675T1
ATE260675T1 AT99968631T AT99968631T ATE260675T1 AT E260675 T1 ATE260675 T1 AT E260675T1 AT 99968631 T AT99968631 T AT 99968631T AT 99968631 T AT99968631 T AT 99968631T AT E260675 T1 ATE260675 T1 AT E260675T1
Authority
AT
Austria
Prior art keywords
methods
dependent hypertension
treating salt
compositions
treating
Prior art date
Application number
AT99968631T
Other languages
German (de)
English (en)
Inventor
George F Schreiner
Richard J Johnson
Original Assignee
Scios Inc
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scios Inc, Univ Washington filed Critical Scios Inc
Application granted granted Critical
Publication of ATE260675T1 publication Critical patent/ATE260675T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT99968631T 1998-09-09 1999-09-09 Methoden zur behandlung der salzabhängigen hypertonie ATE260675T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9969498P 1998-09-09 1998-09-09
US12640699P 1999-03-26 1999-03-26
US12661599P 1999-03-27 1999-03-27
PCT/US1999/020481 WO2000013703A2 (en) 1998-09-09 1999-09-09 Methods of treating hypertension and compositions for use therein

Publications (1)

Publication Number Publication Date
ATE260675T1 true ATE260675T1 (de) 2004-03-15

Family

ID=27378887

Family Applications (2)

Application Number Title Priority Date Filing Date
AT99968631T ATE260675T1 (de) 1998-09-09 1999-09-09 Methoden zur behandlung der salzabhängigen hypertonie
AT99946776T ATE253934T1 (de) 1998-09-09 1999-09-09 Verwendung eines angiogenen faktors zur behandlung von mikrovaskulären angiopathien

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT99946776T ATE253934T1 (de) 1998-09-09 1999-09-09 Verwendung eines angiogenen faktors zur behandlung von mikrovaskulären angiopathien

Country Status (13)

Country Link
US (3) US6352975B1 (https=)
EP (2) EP1112083B1 (https=)
JP (2) JP2002524421A (https=)
AT (2) ATE260675T1 (https=)
AU (2) AU5910599A (https=)
BR (2) BR9913564A (https=)
CA (2) CA2340320C (https=)
DE (2) DE69912815T2 (https=)
DK (2) DK1112083T3 (https=)
ES (2) ES2211165T3 (https=)
IL (2) IL141687A0 (https=)
PT (2) PT1109571E (https=)
WO (2) WO2000013703A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6352975B1 (en) * 1998-09-09 2002-03-05 Scios Inc. Methods of treating hypertension and compositions for use therein
US6783954B2 (en) * 1999-03-05 2004-08-31 Compugen Ltd. VEGF nucleic acid and amino acid sequences
IL148674A0 (en) * 1999-11-02 2002-09-12 Genentech Inc Modulation of enos activity and therapeutic uses thereof
US7078382B1 (en) 1999-11-02 2006-07-18 Genentech, Inc. Modulation of eNOS activity and therapeutic uses thereof
US20030129251A1 (en) 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
US7129222B2 (en) * 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
DE60235761D1 (de) 2001-08-01 2010-05-06 Univ Bristol Clifton Isoform des vegfs
EP1427323A4 (en) * 2001-08-20 2004-09-15 Univ Virginia USE OF S-NITROSOTHIOL SIGNALING TO TREAT BREATH CONTROL DISORDERS
US7981863B2 (en) * 2001-09-19 2011-07-19 Neuronova Ab Treatment of Parkinson's disease with PDGF
US7795213B2 (en) 2001-12-13 2010-09-14 Posco Methods of contacting β amyloid protein with VEGF
US20030171556A1 (en) * 2001-12-13 2003-09-11 Chi-Bom Chae Beta-amyloid binding factors and inhibitors thereof
US7335362B2 (en) 2002-07-19 2008-02-26 Beth Israel Deaconess Medical Center Methods of treating pre-eclampsia or eclampsia
JP2006068401A (ja) * 2004-09-03 2006-03-16 Kyushu Institute Of Technology 人工血管
CN101277704A (zh) * 2005-04-12 2008-10-01 因特拉迪格姆公司 用于治疗癌症及其它新血管生成疾病的RNAi治疗剂的组合物和方法
US7893244B2 (en) * 2005-04-12 2011-02-22 Intradigm Corporation Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
US8440619B2 (en) * 2005-08-31 2013-05-14 National University Corporation Kagawa University Utilization of hypertension/hypercardia-preventing effect of D-allose
ES2600781T3 (es) * 2008-12-04 2017-02-10 Curna, Inc. Tratamiento para enfermedades relacionadas con el factor de crecimiento del endotelio vascular (vegf) mediante la inhibición de transcritos antisentido naturales de vegf
GB0921525D0 (en) * 2009-12-08 2010-01-27 Isis Innovation Product and method
WO2018183625A1 (en) 2017-03-30 2018-10-04 Wake Forest University Health Sciences Methods of treatment for kidney disease
CN113418940B (zh) * 2021-06-24 2023-03-14 电子科技大学 一种基于x射线示踪颗粒的检测方法及检测装置

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456550A (en) 1982-11-22 1984-06-26 President And Fellows Of Harvard College Vascular permeability factor
US5240848A (en) 1988-11-21 1993-08-31 Monsanto Company Dna sequences encoding human vascular permeability factor having 189 amino acids
ATE152626T1 (de) 1989-03-24 1997-05-15 Univ California Endothelialer zellwachsfaktor, isolierung und expression
US5332671A (en) * 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5219739A (en) 1989-07-27 1993-06-15 Scios Nova Inc. DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121
US5240714A (en) * 1989-08-29 1993-08-31 Rof Jose M S Non-digoxin-like Na+, K+ -ATPase inhibitory factor
US5318957A (en) * 1992-09-02 1994-06-07 The United States Of America As Represented By The Department Of Health And Human Services Method of stimulating angiogenesis
KR100695590B1 (ko) * 1996-11-01 2007-03-14 아크 테라퓨틱스 리미티드 산화질소 또는 프로스타시클린 생산을 자극하는 약제의 치료학적 용도 및 전달 기구
US6485942B1 (en) * 1997-02-14 2002-11-26 Genentech, Inc. Variants of vascular endothelial cell growth factor having altered pharmacological properties, and recombinant methods of production
US6352975B1 (en) * 1998-09-09 2002-03-05 Scios Inc. Methods of treating hypertension and compositions for use therein

Also Published As

Publication number Publication date
IL141687A0 (en) 2002-03-10
WO2000013702A3 (en) 2000-09-08
CA2340728C (en) 2007-11-27
WO2000013702A2 (en) 2000-03-16
CA2340320A1 (en) 2000-03-16
JP2002532382A (ja) 2002-10-02
DE69912815T2 (de) 2004-10-21
CA2340728A1 (en) 2000-03-16
JP2002524421A (ja) 2002-08-06
BR9913564A (pt) 2001-05-22
ES2211165T3 (es) 2004-07-01
DE69915310T2 (de) 2005-03-10
US20020193288A1 (en) 2002-12-19
WO2000013703A2 (en) 2000-03-16
IL141686A0 (en) 2002-03-10
ATE253934T1 (de) 2003-11-15
BR9913533A (pt) 2001-06-05
DK1109571T3 (da) 2004-06-21
DK1112083T3 (da) 2004-03-08
EP1109571B1 (en) 2004-03-03
AU5910599A (en) 2000-03-27
DE69912815D1 (de) 2003-12-18
CA2340320C (en) 2006-11-14
EP1112083A2 (en) 2001-07-04
EP1112083B1 (en) 2003-11-12
US6352975B1 (en) 2002-03-05
EP1109571A2 (en) 2001-06-27
ES2216630T3 (es) 2004-10-16
AU6028599A (en) 2000-03-27
PT1109571E (pt) 2004-05-31
DE69915310D1 (de) 2004-04-08
WO2000013702A9 (en) 2000-10-19
WO2000013703A3 (en) 2000-07-06
PT1112083E (pt) 2004-03-31
US20040224885A1 (en) 2004-11-11
WO2000013703A9 (en) 2000-06-02

Similar Documents

Publication Publication Date Title
ATE260675T1 (de) Methoden zur behandlung der salzabhängigen hypertonie
EP1303299A4 (en) COMPOSITIONS AND METHODS ENHANCE IMMUNOGENICITY OF ANTIGENS
BR9707819A (pt) Imunogenos peptidicos
DE69935345D1 (de) Methoden und zusammensetzungen zur prävention und behandlung der anämie
EP1324780A4 (en) METHODS OF TREATING CARDIAC ARRHYTHMIA
ATE371475T1 (de) Methoden zur behandlung der hautpigmentierung
DE60043229D1 (de) Zusammensetzung zur gefässbeschichtung
ATE294158T1 (de) Ein monoether von probucol und methoden zur hemmung der vcam-1 expression
ATE219074T1 (de) Neue salzform von pantoprazol
DK1411916T3 (da) Fremgangsmåder og materialer til behandling af testosteronmangel hos mænd
ATE363531T1 (de) Claudin polypeptide
ATE279208T1 (de) Verfahren und stoffe zur behandlung des prostatakarzinomes
TR199901703T2 (xx) Siklooksijenaz-2 inhibit�rlerini anti-anjiyojenik ajanlar olarak kullanma y�ntemi.
DK0885005T3 (da) Anvendelse af dehydroepiandrosteron og aromatasehæmmere til fremstilling af et lægemiddel til behandling af en relativ og absolut androgenmangel hos mænd
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
ATE476987T1 (de) Zusammensetzungen und methoden zur behandlung von candidosen
DE69915690D1 (de) Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen
DE59811153D1 (de) Synergistisch wirkende zusammensetzungen zur selektiven bekämpfung von tumorgewebe
DK1189615T3 (da) Endoparasiticid synergistisk kombination indeholdende cykliske depsipeptider og piperaziner
ATE291425T1 (de) R-eliprodil zur behandlung von glaucoma
DE59805246D1 (de) Tissue-faktor zur beeinflussung von gefässbildung
EP1447089A3 (en) Methods of treating hypertension and compositions for use therein
ATE292970T1 (de) Topische zusammensetzung enthaltend brucin und ihre verwendung zur behandlung von hautschäden

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1109571

Country of ref document: EP

REN Ceased due to non-payment of the annual fee